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O Fígado é o principal órgão regulador do metabolismo do ferro. Distúrbios 
relacionados com a sobrecarga de ferro podem ser devido a factores 
genéticos, como na HH com mutações conhecidas para o gene HFE, mas 
também associados a doença hepática crónica, como a NASH. Vários estudos 
relatam uma elevada frequência das mutações do gene HFE em pacientes com 
NASH. Do modelo genético e imunológico da HH, sabe-se que estes doentes 
têm um haplótipo conservado na região MHC que está associado com o 
número de células CD8 + T. Os indivíduos que têm baixos números de 
linfócitos T CD8 +, acumulam mais ferro no tecido hepático do que os têm 
elevado número de linfócitos CD8+ T. A partir destes pressupostos, 
questionamos se este efeito é também observado em pacientes com NASH e 
se a região MHC, utilizando os marcadores genéticos do modelo da HH, teria 
qualquer impacto na gravidade da doença.  
 
Foram analisados dados clínicos, imunológicos e histopatológicos de 59 
pacientes com NASH. Pacientes com NASH foram genotipados para oito 
marcadores genéticos na região MHC correlacionados com o número de 
células CD8 + T (HLA-A, B e C; PGBD1; ZNF193 e HFE) e dois perto do HLA-A: 
RS7240078 e RS4713207. Controlos (264 indivíduos) foram utilizados para a 
comparação das frequências de todos os alelos, excepto para PGBD1 e ZNF193 
onde um subgrupo (n = 56) foi usado.  
 
Não foram observadas diferenças estatisticamente significativas entre NASH e 
controlos para os marcadores genéticos e dados imunológicos. Foi encontrada 
uma associação entre números de linfócitos CD8 + T com fibrose e inflamação, 
sendo estas variáveis inversamente correlacionados. Os alelos HLA-A33 e HLA-
A29 foram encontrados em dois haplótipos conservados na região definida 
pelos marcadores. O haplótipo contendo o HLA-A 33 encontra-se associado à 
presença de fibrose simultaneamente com uma baixa média de células CD8 + 
enquanto os indivíduos com o haplótipo do HLA-A 29 não desenvolviam 
fibrose e tinham linfócitos CD8+T mais elevados. 
 
Os resultados demonstram que o perfil imunológico dos NASH não reflecte o 
mesmo padrão da HH. Este facto pode ser devido à condição inflamatória dos 
NASH, porque as células CD8+ T à periferia não reflectem o que ocorre nos 
tecidos como é observado no modelo da HH. 
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abstract 
 
 
 
 
 
 
Liver is the main organ in regulation of iron metabolism. Disorders of iron 
overload can be due to genetic factors, as in HH associated with the HFE gene 
mutations, and also associated with chronic liver disease, as in NASH. Several 
studies report a high frequency of HFE mutations in NASH patients. From HH 
genetic and immunological model it is known that a conserved haplotype in 
the MHC region is associated with CD8+T cell numbers. Individuals that have 
low CD8+T cell numbers have more iron accumulated in liver tissue, than 
individuals with high CD8+T cells. From these assumptions, we questioned if 
this effect is also seen in NASH patients and if the MHC region, using the 
genetic markers of HH, would have any impact in disease severity. 
Clinical, immunological and histopathological data from 59 NASH patients 
were analyzed. NASH patients were genotyped for eight genetic markers of 
the MHC region correlated with CD8+T cell numbers (HLA –A, B and C; PGBD1; 
ZNF193; HFE; RS7240078 and RS4713207. Controls (264 individuals) were used 
for comparing frequencies of all genes except for PGBD1 and ZNF193 where a 
subgroup (n=56) was used. 
No statistically significant differences were observed between NASH and 
controls for the genetic markers and immunological data. A negative 
association was found between CD8+T cell numbers and both fibrosis and 
inflammation. Two conserved haplotype were found with HLA-A33 and HLA-
A29. HLA-A33 haplotype was found associated with the presence of fibrosis 
and low CD8+T cells average while haplotype carrying HLA-A*29 had less 
fibrosis and high CD8+T cells. 
In conclusion, the results show that immunological profile in NASH patients do 
not reflect the same picture as in HH. This may be due to a different 
distribution of lymphocytes cells between blood and tissues given the 
inflammatory condition in NASH.  
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1-INTRODUCTION 
1.1 IRON IN LIVER DISEASE 
 
The liver is the largest parenchymal organ in the body with multiple metabolic 
functions. Its normal function is vital for the intermediary metabolism of carbohydrates, 
fats and proteins. It is the organ that synthesizes all major plasma proteins, except 
immunoglobulins. The most important one is albumin. Others are coagulation proteins, 
proteins of transport of hormones, vitamins and many other biologically active 
substances [1]. By secreting the hormone peptide hepcidin, the liver is now recognized to 
play a central regulatory role in iron homeostasis [2]. In humans, there is no known 
excretory pathway for iron, so severe iron overload may result from excessive iron 
absorption, caused by a genetic defect known as hereditary Hemochromatosis (HH), or as 
a consequence of parenteral administration of iron, mainly in the form of blood 
transfusions. In addition, mild or moderate forms of iron overload are commonly 
observed associated with several forms of chronic liver disease, either with chronic 
alcohol consumption, viral hepatitis, or dysmetabolic disorders as non-alcoholic fatty liver 
disease (NAFLD). 
1.2 HEREDITARY HEMOCHROMATOSIS 
 
Hereditary Hemochromatosis (HH) is a homozygous-recessive inherited disorder 
that results in iron overload in the parenchymal cells of the liver and other organs due to 
excessive intestinal absorption. Tissue iron overload causes damage and dysfunction of 
the target organs. Total body iron pool ranges from 2 to 6 g in normal adults, of which 
0.5g is stored in the liver (98% in hepatocytes). In HH, the net iron accumulation ranges 
from 0.5 to 1.0 g/year and total iron stored may exceed 50g, one third will be in the liver 
[1]. Manifestations of the disease appear after 20g of iron accumulation. The disease is 
characterized by clinical, genetic and immunological features. 
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The most severe clinical consequences are: hepatic cirrhosis, diabetes, arthritis, 
sexual dysfunction due to hypogonadotropic hypogonadism, cardiomyopathy, 
hiperpigmentation, and hepatocellular carcinoma [3]. Treatment of HH consists in regular 
phlebotomies for depletion of iron stores, establishing the serum ferritin level less than 
50ng/ml [4]. 
Genetically, the most common form of HH is associated with the HFE gene. This 
gene was discovered by Feder et al. in the short arm of chromosome 6 at 6p21.3, near the 
HLA gene locus [5]. The search for this gene started long ago (1975), by Simon and 
collaborators that described for the first time an association between HH and HLA 
antigens: HLA-A and HLA-B in the major histocompatibility complex region (MHC). After 
several family studies, it was confirmed the autossomic recessive transmission of HH in 
linkage with the HLA-A*03-B*07 haplotype. The HFE gene, discovered later in 1996 by 
Feder et al., encodes an HLA class I-like molecule. The protein structure consists in a 
transmembrane region and a small cytoplasmatic portion (Fig.1). The structural 
organization of HFE molecule includes a signal sequence, alpha-1 and alpha-2 domains 
that recognizes the peptide, and an immunoglobulin domain alpha-3. For protein surface 
expression, the correct conformation of immunoglobulin domain alpha-3 is needed with a 
non-covalent interaction with β2 microglobulin molecule (β2-m) and presentation of 
peptide binding site formed by α1 and α2. The peptide binding site interacts with 
transferrin receptor (TfR1) that binds to circulating transferrin and regulate iron 
homeostasis [1, 4]. 
 Initially, two mutations were described in the HFE gene: H63D and C282Y. The 
C282Y mutation is more frequent among Caucasians (incident between 1.3- 14%), and is a 
cysteine-to-tyrosine replacement at amino acid 282 that inactivates this 343 amino-acid 
protein. This is due to a single G--»A transition at nucleotide 845 (G845A). The result is 
the alteration of the α3 domain and consequently elimination of the heterodimer HFE- 
β2m eradicating the cell surface expression of the molecule [4, 6]. This mutation is 
present in more than 83% in homozygosity of patients with HH. It is estimated that, for 
the Caucasian population, this homozigoty is approximately 0.3-1.0% [5, 7]. 
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Figure 1 Schematic diagram of a MHC class I molecule (adapted from [1]). 
 
 The H63D mutation has a high frequency in Europe, above 15% [4]. It is associated 
to a mild phenotype of HH, when in heterozigoty with C282Y. It consists in a substitution 
of a cytosine to a guanine in the nucleotide 187, so it would appear a histidine instead of 
an aspartate at amino-acid 63. It does not affect the cell surface expression but alters the 
α1 domain modifying the affinity of transferrin to its receptor [4]. 
1.3 IRON AND IMMUNITY 
 
The HFE gene belongs to the MHC class I genes family. The MHC is an extremely 
important group of genes involved in the immunological system. The postulate that the 
immunological system participates in the monitorization of iron toxicity was described by 
De Sousa in 1978 [8], based on her observations on lymphocytes traffic and positioning. 
It was postulated that these cells were involved in a protector mechanism against 
metal toxicity through recognition and binding of metals [9]. This fact motivated 
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immunological studies in HH patients. Iron is an important nutrient for cell division in 
general. In the case of lymphocytes, it is known that activation and expansion depend on 
the expression of transferrin receptors needed for DNA synthesis and cellular division. It 
is also known that both T cells (inactivated and activated) synthesize ferritin [9]. 
In HH patients, it was observed abnormally high CD4/CD8 lymphocytes T ratios 
displaying a faster re-entry of iron in circulating transferrin after heavy phlebotomies, 
comparing with patients with normal CD4/CD8 ratios [10, 11]. 
The high CD4/CD8 ratios were due to low numbers of CD8+ T cells, which are 
inversely correlated with the amount of iron accumulated during time, reflecting a more 
severe disease [5, 12, 13]. Low numbers of CD8+T cells in the peripheral blood are 
associated with low numbers of these cells in the liver [14]. Patients with “low CD8+ T 
cells profile” have a more severe accumulation of iron with age, in contrast with patients 
with “high CD8+ T cells profile” [12]. Therefore, the CD8+T cells are used as prognostic 
marker for the accumulation of iron with age.  
The most common form of HH is associated with C282Y mutation of the HFE gene. 
Although there is a great homogeneity in the genotype, the clinical phenotype is variable. 
Heterogeneity observed in the amount of iron accumulated in the patients’ tissues may 
be explained by the existence of modifying factors as: sex and age of the individuals but 
also by environmental factors and the involvement of others genes that may interact 
together. 
The existence of theses modifying factors may explain the low clinical penetrance 
of the disease. One of the modifiers that have been referred is the CD8+T cell profile. 
Recently, these cells were shown to be genetically regulated by gene/s at the MHC 
region. Studies in families with HH, allowed the observation of LD between particular 
HLA-A types and CD8+T cell counts. The inheritance of two copies of haplotypes carrying 
the HLA-A alleles: A*03, A*02 and A*01 was associated with low lymphocytes (0.30±0.14 
x106/ml). Patients carrying one copy of that haplotype had an intermediate number of 
CD8+T cells (0.46±0.19 x106/ml) and patients without any of those haplotypes had the 
highest CD8+T cells numbers (0.79±0.19 x106/ml) [7]. 
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Later, Vieira and collaborators identified a region in a normal population next to 
D6S105-150 as being the most probable localization of the gene that influences the levels 
of CD8+T cells [15]. This same region had been proposed some years ago, as a candidate 
region to look for modifiers of HH [16]. Pratiwi and collaborators conducted an extensive 
genetic analysis of genes in HFE region in a Australian population of HH. Two distinct 
peaks of association were identified, separated by 2 Megabases, which were not 
compatible with a single gene disorder [16]. One of the peaks found was at the region of 
the D6S2239, at 14 Kilobases (Kb) from HFE. The other corresponded to D6S105, located 
about 200 Kb from D6S2222 (Fig.2). This observation is compatible with the presence of a 
genetic modifier of the disease near this region [16]. 
 
Figure 2 Physical map of genetic markers used by Cruz et al. (2008) study and their relative 
location at scale.  
 
 Haplotypes that contains the HLA-A*1 allele are not the same in normal 
population and in C282Y homozygous patients, what explains why the allele A1 is 
associated with high numbers of CD8+T lymphocytes in normal population and low in HH 
patients [15]. 
 The frequent presence of haplotype C282Y in linkage desiquilibrium with the allele 
HLA-A*03, and less relevant with HLA-B*07 associated to lower lymphocytes, led to infer 
the ancestral haplotype where the mutation C282Y occurred. Recombination in the 
region in between HLA-A and D6S2222 could have driven the C282Y mutation to others 
haplotypes found in control population (A*11, A*23, A*24, A*26, A*29, A*31, A*32, A*33 
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and A*68), leading to extinction of the linkage with the responsible “low CD8*T cells” 
profile gene [7]. 
 Toomajian et al. (2003) found one triallelic polymorphism (A/C/G) at site 7633 
located in first intron in HFE gene [17]. They found that 7633-A allele, was under positive 
selection in normal population, suggesting that it has hitchhiked on a particular large 
region. Vieira and collaborators showed an association between HFE-7633-A and 
microssatellite D6S105-150 predicting high CD8+T cell numbers [15]. 
 In a recent publication in HH patients, Cruz et al. (2008) conducted a more 
extensive haplotype study and covered 1 megabase with 7 different markers surrounding 
the D6S105 microssatelite. The markers used included 5 SNPs in the genes: ZSCAN12 (Zinc 
finger and Scan Domain12), PGBD1 (piggyback transposable element derived 1), ZNF193 
(Zinc finger protein 193), ZNF165 (Zinc finger protein 165), ZNF184 (Zinc finger protein 
184); and two microsatellites D6S2222 and D6S105 [18](Fig.2). 
The SNPs were selected based on their location and frequencies in the population. 
In a sample of 56 C282Y homozygous patients, a total of 112 haplotypes were obtained. 
The most common haplotype observed, with a frequency of 73%, was: ZSCAN12-A, 
PGBD1-A, ZNF193-A, ZNF165-T, D6S2222-247, D6S105-150. ZNF184-G. The high 
frequency of this haplotype suggests that it might be the ancestral one where C282Y 
mutation appeared. The results also revealed that 3 SNPs tested: PGBD1 (A/G), ZNF193 
(A/G) and ZNF165 (T/G) each one were statistically significant associated with CD8+ T cell 
numbers. Those polymorphisms define a conserved haplotype with 500kb predicting 
CD8+T cells count, higher than each SNP separately. The haplotype constituted by the 
alleles PGBD1-A, ZNF193-A and ZNF165-T, designated A-A-T, was associated with low 
CD8+T numbers (0.37±0.17 x 106/ml) in opposite with the haplotype PGBD1-G, ZNF193-G 
and ZNF165-G, designated G-G-G, reflecting an high number of those cells (0.55±0.14 
x106/ml) [18]. Moreover, the A-A-T haplotype when present in homozygosity (A-A-T/A-A-
T) was associated with higher hepatic iron accumulation than in heterozygous patients for 
this haplotype (A-A-T/G-G-G) that exhibit a less deposition of iron in tissues. The G-G-G 
haplotype was also found in 10 Canadian patients [18]. This leads to the hypothesis that 
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the G-G-G haplotype could have a protective role in patients` clinical features and the 
same associations with CD8+Tcells and iron stores were observed. One limitation of this 
study is the little representation of G-G-G haplotype in these patients [18]. 
Clinical implications of these findings may be extremely important, because the 
genotype of the 3 SNPs can distinguish two groups of patients according to different 
prognostics. Patients with G-G-G haplotype may have a different surveillance in relation 
to therapeutic strategies as they may accumulate less iron and may need fewer 
phlebotomies.  
1.4 NON-ALCOHOLIC FATTY LIVER DISEASE  
 
 Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disorders of the 
liver due to causes other than alcohol that ranges from simple accumulation of fat 
exceeding 5-10% by weight (steatosis), to non-alcoholic steatohepatitis (NASH) with 
advanced fibrosis which can lead to cirrhosis and hepatocellular carcinoma. It is possible 
to distinguish a condition of simple fatty liver, characterized by the histologic finding of 
steatosis, from a state of NASH characterized by hepatocellular injury/inflammation with 
or without fibrosis. Even though, the frequency of NASH disorder is increasing [19-21]. 
 NAFLD is considered to be the hepatic manifestation of insulin resistance (IR) [22]. 
The prevalence of NAFLD is around 20-30% in the general population. Only 5-17% of 
NAFLD patients progress to NASH. It is unclear why some patients who develop NAFLD go 
on to develop NASH while others do not. The occurrence of NASH is clinically important 
because approximately 15-25% of these patients will progress to cirrhosis [19]. From this 
cirrhotic stage, 30-40% of patients will develop a liver-related death over a 10-year period 
[19]. 
 Although the initial stage of NASH is usually asymptomatic, it may be associated 
with non-specific symptoms such as upper abdominal pain, malaise or fatigue. In terms of 
histology NASH can progress from steato-inflammation to bridging fibrosis, cirrhosis and 
hepatic failure [20].  
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 The laboratory features of the disease traduce abnormally high levels of serum 
concentrations of aspartate transaminase (AST) and alanine transaminase (ALT). This 
pattern of high AST and ALT concentrations helps to distinguish NAFLD from alcoholic 
hepatitis where AST values are elevated in relation to ALT concentration. In NAFLD it is 
common to observe elevations in serum ferritin with normal transferrin saturation and 
mild hepatic iron staining in liver biopsies [20]. However, the serum ferritin may also be 
increased in other inflammatory conditions and it is not clear what event comes first. 
 The physiopathology of NASH remains a two-hits hypothesis, the first hit consists 
of a metabolic syndrome often associated to obesity or overweight patients, but also 
including insulin resistance and diabetes. For NAFLD progression to NASH, a second hit is 
needed with the occurrence of ROS (Fig.3) [19].  
 
 
Figure 3 Scheme of suggested pathogenesis of NASH as a two hits process (Adapted from [19]). 
 
 Bonkovsky et al. studied the association of HFE mutations with NASH in a group of 
57 patients in USA. The results showed an increased prevalence of the HFE mutations in 
homozygosity or heterozygosity combined in NASH patients (69.4%) relative to a control 
population with 348 subjects (40.5%, p=0.001). Patients with mutations were the ones 
with higher levels of serum ALT [20]. 
 While in NASH cell injury begins with fat deposition in liver (NAFLD) as a result of 
insulin resistance and increased fat mass, in HH cell injury results directly from iron 
deposition consequence of an imbalance of iron absorption due a genetic cause.  
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 In both situations, oxidative stress is involved. In NASH patients iron may be an 
additional factor for disease progression. Oxidative stress reactions (ROS) in the liver can 
be provoked by alcohol, hepatitis C virus or insulin resistance associated to obesity. Iron 
overload may exacerbate the ROS and promote liver injury and fibrosis. In some cases, 
ROS may directly promote carcinogenesis. Oxidative stress can also depress hepcidin 
expression in hepatocytes by reduced activity of C/EBPα. The presence of HFE C282Y 
mutation, can depress hepcidin even further and increase iron absorption and 
accumulation in the liver, generating more ROS (Fig.4). 
 The degree of hepatic fibrosis shows a positive association between hepatic iron 
concentration and duration of exposure to excess iron [2]. In HH it has been 
demonstrated that excess hepatic iron promotes the activation of hepatic stellate cells, 
reversible by iron removal [23].  
 
Figure 4 The role of Iron in liver disease. (adapted from [2]). 
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1.5 OBJECTIVES 
 
 It is known that NASH is associated with increased oxidative stress (ROS) and 
mitochondrial dysfunction. Iron overload is a producer of oxidative stress, therefore it 
appears that iron may exacerbate NASH pathology. The prevalence of the HFE mutations 
in NASH is reported to be higher than in controls, suggesting that iron may play a role is 
this pathogenesis. The risk of developing fibrosis is an interplay between genetic 
influences (as the HFE mutations) and environmental factors [24]. The predictive 
haplotype G-G-G, localized at MHC region described recently in HH, might also be 
involved in the progression of NASH, a mechanism that could be through the effect of 
CD8+T lymphocytes. 
 In the present thesis a NASH population is analyzed in relation to several genetic 
markers at MHC Class I region, the same markers that in HH are correlated with CD8+T 
cells and iron stores. We test the hypothesis if, similarly to HH, there are a relationship 
between the MHC region including HLA genes, haplotype PGBD1, ZNF193, ZNF165 and 
the HFE mutations, and the severity of NASH measured by the degree of steatosis, 
fibrosis, and inflammation. This hypothesis that the same modifiers of expression 
observed in HH could also modify the clinical course in NASH is very attractive. 
 MHC-Class I markers in non-alcoholic steatohepatitis  
 
11 
2-MATERIAL AND METHODS 
 
2.1 POPULATION STUDIED 
2.1.1 NON-ALCOHOLIC STEATOHEPATITIS PATIENTS 
 A total of fifty-nine NASH patients were included in this study. They were 
diagnosed and followed up at Gastroenterology Clinics at Eduardo Santos Silva Hospital, 
Gaia. Forty-three were males with mean age 45 ± 12 years (range 26-78), and sixteen 
were females with mean age 45 ± 12 years (range 31-68). The diagnosis of NASH was 
established by a combination of clinical and histopathological features: consumption of 
alcohol below 20g/day and liver biopsy with steatosis and lobular inflammation (with 
absence of features suggestive of other diagnosis such as autoimmune, granulomatous or 
viral hepatitis). Clinical and laboratory data included in this work were partially reviewed 
from clinical files of the subjects or were determined for this study. 
 
2.1.2 CONTROLS  
 A total of 264 apparently healthy unrelated subjects previously analyzed (Cruz et 
al, 2004) [25] were included in this study. They were blood donors recruited from the 
Blood Bank of Santo António Hospital, Porto. One hundred and sixteen were males with 
mean age 43 ± 13 years (range 20-76), and 148 were females with mean age 45 ± 13 years 
(range 18-88). These subjects were used as controls for immunological parameters (total 
lymphocytes, CD4+ and CD8+T cell numbers), for estimating HLA-A, -B, –C and HFE 
mutations normal frequencies. From this starting sample, a subgroup of 56 subjects was 
randomly selected and genotyped for four SNP markers (see Genetic characterization of 
subjects). Twenty-seven were males with mean age 40 ± 11 years (range 23-64), and 
twenty-six females with mean age 39 ± 12 years (range 23-62). 
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2.1.3 INFORMED CONSENT AND APPROVAL OF THE STUDY 
 Informed consent from patients and controls was obtained according to the 
Helsinki declaration. The study was approved by the ethical committee of Eduardo Santos 
Silva Hospital and Santo António Hospital. 
 
2.1.4 GENERAL CHARACTERIZATION OF PATIENTS 
 Clinical data from patients were carefully reviewed from their clinical files by one 
dedicated physician. A liver biopsy was performed in all patients and all have steatosis 
and inflammation, as part of diagnosis criteria. In addition, fibrosis and siderosis was also 
evaluated. Scoring of these parameters was performed always by the same physician. 
Steatosis was graded 1-3: 22 patients with grade I, 19 with grade II and 14 with grade III 
(in four patients grade was not available); inflammation was graded 1-3: 46 with grade I, 
eight with grade II and two grade III (in three patients grade was not available); fibrosis 
was graded 0-4: 33 patients without fibrosis, 15 with grade I, five with grade II, two with 
grade III and one with grade IV (in three patients grade was not available); siderosis was 
graded 0-3: 27 without siderosis, 18 with grade I, eight with grade II and one with grade III 
(in five patients grade was not available). 
 Parameters included in the study were: body mass index (BMI), biochemical 
parameters of liver disease (alanine aminotransferase-ALT, aspartate aminotransferase-
AST, gamma-glutamyl transferase-GGT) and biochemical parameters of iron metabolism 
(serum iron, transferrin saturation TfSat and serum ferritin). 
 Immunological parameters analyzed included peripheral blood total lymphocyte 
counts and CD4+ and CD8+ T-lymphocyte counts. Total lymphocyte counts were 
determined in an automatic blood cell counter (Advia 120. Hematology Systems, Bayer®). 
CD4+ and CD8+ T lymphocytes were determined by flow cytometry as described in detail 
elsewhere [25]. 
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2.1.5 GENETIC CHARACTERIZATION OF SUBJECTS  
 Several genetic markers localized at the MHC class I region in the short arm of 
chromosome 6 were previously genotyped or genotyped for the purpose of this study in 
patients and controls (Fig.5). 
 
 These markers include: genotype for HFE gene mutations (C282Y and H63D) and 
for HLA-A, -B, -C. In controls, all subjects had genotype information for HLA-A alleles, 242 
individuals gather information for HLA-B and 207 had genotype for HLA-C. In one patient 
there was no information of HLA genotype. Detailed description of genotype techniques 
was previously published elsewhere [25]. In addition patients and the subgroup of 56 
controls were genotyped for four SNPs, two were localized in the genes: PGBD1 
(rs1997660 at position 28377642bp) and ZNF193 (rs7206 at position 28309117), that 
were previously genotyped in HH patients (Cruz et al 2008)[26]. The other two were 
localized near HLA-A gene: RS724078 at position 1835888 and RS4713207 at position 
2060281 (Fig.5). 
 
2.2 METHODS 
 
 Genomic DNA was extracted using the blood extraction Kit from Promega: 
Maxwell®16 DNA Purification. For genotyping these SNPs, we first performed the 
approach of Allele-Specific PCR (AS-PCR), which consists in designing specific primers that 
will match each SNP polymorphism at the 3'-end of the prime. 
 For assessing the AS-PCR protocol, DNA samples were quantified using the 
Thermo Scientific NanoDrop spectrophotometer and normalized at the concentration of 
Figure 5 Physical map of genetic markers used in this study and their relative distance between 
consecutive marker. 
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70ng/l. Using Oligo 4.0 software, primers to amplify each SNP allele were designed 
respecting the best compatibility parameters between oligonucleotides probes. 
 Only three genetic markers gathered these optimal conditions and were 
genotyped by AS-PCR: PGBD1, ZNF193 and RS724078. The PCR annealing temperatures 
were optimized for each allele amplification (Table 1). 
 
Table 1 Primers used for each SNP allele amplification, with specific annealing temperature, by 
AS-PCR. 
SNP Primers Tª annealing PCR Product 
PGBD1 
FW: 5` TGT TTG GTG TCT TAC TTT A 
53ºC 
G 
54ºC 671bp RV(A):5` CTC  ATT GTT TTC TTC TAT 
RV(G):5` CTC  ATT GTT TTC TTC TAC 
     
ZNF193 
FW: 5`GAA AAG CCG TAT CAG TGC3`  A 
52ªC 
G 
54ºC 382bp RV(A):5`GTA AGA AAG AGG TAA AAT 3` 
RV(G): 5`GTA AGA AAG AGG TAA AAC 3` 
     
RS724078 
FW(A): 5`CTA CTG AGG AAA CAA GCA 3` A 
49ºC 
G 
51ºC 764bp FW(G):5`CTA CTG AGG AAA CAA GCG 3` 
RV: 5` TGA CCA ATG ACC AAT GAT 3` 
 
 Homozygous controls (positive and negative for each allele) were used in all PCR 
reactions. The thermocycler program had the following conditions: initial denaturation 
step at 95ºC (2`), 35 cycles (denaturation step at 95ºC (30``); annealing at specific 
temperature (45``) and extension at 72ºC (2`30) with a final extension at 72ºC (5`). The 
PCR products were stored at 4-8ºC. After the PCR reaction, the products were 
electrophoresed in a 1.5% agarose gel and samples amplification were compared with the 
specific controls. 
 AS-PCR protocol could not be established for the other SNP (RS4713207), since 
oligonucleotide probes in that region couldn´t assure a PCR genotyping. This difficulty was 
overcome by direct sequencing. Furthermore, when results of AS-PCR genotyping for 
PGBD1 and ZNF193 were not in agreement with the expected result, according to the 
most common haplotypes in the sample, those individuals were also sequenced. The 
sequencing protocol begins with a standard PCR with a volume of 25l using specific 
primers to frame the SNP genome region. The sequencing primers used for each gene 
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were those described in table 2 with specific annealing temperature and PCR product 
length. 
 
Table 2 Primers used in sequencing PCR for each SNP gene region and specific annealing 
temperature. 
SNP Primers Tª annealing PCR Product 
PGBD1 
FW:5´AAA ATG TCC CTT TAT GAA T 3` 
50ºC 419bp 
RV:5´CAA ATC TCC GAA AAT CCA A 3` 
    
ZNF193 
FW:5´TCT TTC TTC CTT TCT CCA T 3` 
46ºC 275bp 
RV:5´TCT GTT ATC CTT TGT AGT T 3` 
    
RS724078 
FW: 5`AGC AGC CAG CAT CAC AGA 3` 
52ºC 277bp 
RV:5`ATC ATT GGT CAT TGG TCA 3` 
    
RS4713207 
FW: 5`ATT TTC CTT TAC CTA CCC 3` 
48º C 706bp 
RV: 5` TAT TAT TTT CTG GCT TCT 3` 
    
 
 Amplicons were then electrophoresed and extracted from the agarose gel with 
the QIAquick Gel Extraction Kit (Quiagen, Izasa Portugal, Lda). Sequencing mixs were 
prepared with Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, 
California USA) according to manufacturer instructions and one of the sequencing 
primers. Finally samples were loaded in an ABI Prism 310 Genetic Analyzer Sequencer 
(Applied Biosystems, California USA). 
 
2.3 HAPLOTYPE INFERENCE 
 
 Extended haplotypes were defined using the genotype information of the 8 
genetic markers (Fig.5), using the program PHASE v 2.1 (http://www.stat. 
washington.edu/stephens/phase/) as described previously in Vieira et al. 2007 [15]. In 
some patients the genotype information of the markers rs4713207 (n=4) and rs724078 
(n=16) was missing. In those cases, missing alleles were inferred using PHASE. 
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2.4 STATISTICAL ANALYSIS 
 
 Group means were compared by a parametric (Student’s T test, ANOVA) or non-
parametric (Mann-Whitney and Kruskal-Wallis) tests as appropriate according to variable 
distribution. The Shapiro-Wilk test was used to test the fitness of data to the normal 
distribution, for p>0.05. A normal distribution could be assumed for CD8+T cell numbers 
(p=0.107), TfSat (p=0.128) and serum iron (p=0.068). Independence between categorical 
data and differences between allele frequencies of the genetic markers, between NASH 
patients and controls were tested using the Fisher exact test. When large numbers of 
statistical tests are performed, correction for multiple comparisons is required. This is the 
case of comparisons of frequencies of HLA alleles that are extremely polymorphic. In 
order to overcome this problem the Bonferroni`s correction was applied. 
Severity of NASH was evaluated in liver biopsies by the degree of steatosis, 
inflammation, siderosis and fibrosis. In order to have sufficient number of patients for 
statistical analyses involving these parameters, patients were grouped in two classes for 
each of those parameters: 1 and >1 for inflammation and steatosis and 0 and ≥1 for 
fibrosis and siderosis. Statistical analysis involving these parameters were performed 
using parametric or non-parametric tests, identified above, as appropriate. 
All statistical tests were performed at 0.05 level of significance and all p values are 
two-sided. Data were analyzed by SPSS (Statistical Package for Social Sciences, version 
17.0) software. 
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3-RESULTS 
3.1 GENERAL CHARACTERIZATION OF NASH PATIENTS 
 
 General characterization of patients is shown in Table 3. No statistically significant 
differences were found in any of the parameters analyzed according to gender therefore, 
analyses were performed in males and females together. All subjects had average body 
mass index above the normal ranges, indicating an overweight condition. In the group of 
59 NASH patients, all had average normal values of TfSat and serum iron according to 
reference ranges. Nevertheless, average values of serum ferritin were elevated in both 
males and females in relation to reference ranges. Average values of liver enzymes, ALT, 
AST and GGT, were increased, which is in accordance with NASH physiopathology. 
Considering immunological data, no significant differences were observed between NASH 
and controls in average values of total lymphocytes numbers, CD4+ T cells and CD8+ T 
cells counts (Table 3). 
 In all patients a liver biopsy was performed and all had steatosis and inflammation 
(as part of the diagnostic criteria). Fibrosis and siderosis was also evaluated in the liver 
biopsy. These four parameters were scored as described in Material and Methods (2.1.4). 
These parameters were analyzed between them and studied in relation to liver enzyme 
levels (AST, ALT and GGT) and iron parameters (TfSat, ferritin and serum iron). The grade 
of inflammation was correlated with fibrosis (p<0.0001, r=0.58, R2=0.32) but not with 
steatosis and siderosis. The grade of siderosis was associated with ferritin levels (p=0.035, 
Kruskal-Wallis test), TfSat and serum iron (p=0.0003 and p=0.0002 One-way ANOVA, 
respectively), but not with liver enzymes. Severity of inflammation was associated with 
ALT levels (p=0.051, Kruskal-Wallis test) and was not associated with serum ferritin. 
Severity of fibrosis was associated with mean values of AST (p=0.016, Kruskal-Wallis test) 
and was not associated with serum ferritin levels. 
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Table 3 General characterization of Non-Alcoholic Steatohepatitis patients. 
 
All Patients 
(n=59) 
Males 
 (n=53) 
Females  
(n=16) 
Reference 
values* 
Age 
45±12 
(26-78) 
45±12 
(26-78) 
45±12 
(33-68) 
- 
Body Mass Index (Kg/m
2
) 
29.8±5.0 
(21-48) 
28.8±3.6 
(21-35) 
32.1±7.1 
(21-48) 
18.5-25 
Transferrin saturation 
(%) 
36±12 
(16-74) 
37±13 
(16-74) 
33±11 
(15-52) 
15-45 
Serum ferritin (ng/ml) 
282±255 
(17-949) 
323±254 
(17-949) 
307±248 
(12-492) 
11-150 (F) 
11-282 (M) 
Serum Iron (g/dl) 
112±33 
(49-225) 
112±36 
(49-225) 
112±26 
(63-147) 
53-167 
Hepatic Iron 
Concentration (g/g) 
53.9±75.2 
(7-434) 
62.1±82.6 
(7-434) 
31.6±44.6 
(1.3-183) 
<50 
Serum ALT (IU/l) 
73±41 
(26-206) 
70±40 
(31-206) 
79±45 
(26-176) 
10-44 
Serum AST (IU/l) 
48±26 
(18-141) 
45±26 
(26-141) 
54±26 
(21-107) 
10-34 
Serum GGT (IU/l) 
109±106 
(25-664) 
111±116 
(16-301) 
103±80 
(25-340) 
10-66 
Total lymphocytes 
(x10
6
/ml) 
2.04±0.52 
(1.20-3.80) 
1.99±0.43 
(1.20-2.96) 
2.18±0.71 
(0.99-3.80) 
2.14±0.53  
(0.89-3.75) 
Total CD4+ T cells 
(x10
6
/ml) 
0.85±0.26 
(0.45-1.72) 
0.77±0.18 
(0.46-1.17) 
1.01±0.32 
(0.68-1.35) 
0.92±0.28  
(0.32-1.77) 
Total CD8+ T cells 
(x10
6
/ml) 
0.44±0.17 
(0.27-0.91) 
0.44±0.18 
(0.07-0.91) 
0.43±0.17 
(0.21-0.70) 
0.43±0.17  
(0.025-0.98) 
*Reference values of the clinical biochemistry laboratory of the SAH, except for immunological data which 
reference values were determined from 264 unrelated healthy subjects used in a previous study. 
 
 
3.2 GENETIC CHARACTERIZATION OF NASH PATIENTS 
3.2.1 ALLELE FREQUENCIES OF HFE MUTATIONS, HLA-A, -B AND –C ALLELES AND SNP 
MARKERS 
 All patients were genotyped for HFE mutation and HLA-A, -B and –C alleles and 
frequencies were compared with 264 controls previously studied (Cruz et al. 2004, [25]), 
using Fisher exact test. The allele frequencies of HFE mutations in this group of NASH 
patients were not statistically different than controls (Table 4). The C282Y mutation had 
an allele frequency of 0.017 (0.025 in controls, n.s.) and the H63D mutation had a 
frequency of 0.241, that was slightly higher than in controls (0.191, n.s.) (Table 4). 
 
 MHC-Class I markers in non-alcoholic steatohepatitis  
 
19 
Table 4 Comparison of allele frequencies of HFE mutations between NASH patients and controls. 
HFE Allele Frequency NASH patients (n=58) Controls (n=264)* p value 
C282Y 0.017 (n=2) 0.025 (n=13) 0.75 n.s 
H63D 0.241 (n=28) 0.191 (n=100) 0.25 n.s 
* A previously studied population of 264 unrelated healthy subjects was used as controls. Allele frequencies 
were compared using the Fisher exact test. 
 
 No statistically significant differences were found between frequencies of HLA-A 
alleles in NASH patients and controls. In HLA-B alleles, only with HLA-B*49 was found a 
significant difference (p=0.022) between these groups, with a higher frequency in NASH 
patients (9/116=0.078) than in controls (13/484=0.027). In HLA-C alleles, HLA-C*4 had a 
statistically significant (p=0.032) lower frequency among NASH patients (11/116=0.095) 
comparing with controls (73/414=0.176). After Bonferroni` correction these associations 
were no longer statistically significant (Table 5). 
 
Table 5 Comparison of allele frequencies of HLA-A, -B  and -C between NASH patients and 
controls. 
HLA-A 
NASH 
(n=116 alleles) 
Controls * 
(n=528 alleles) 
p value 
HLA-A*1 0.112 (n=13) 0.123 (n=65) n.s 
HLA-A*2 0.276 (n=32) 0.280 (n=148) n.s 
HLA-A*3 0.086 (n=10) 0.095 (n=50) n.s 
HLA-A*11 0.034 (n=4) 0.051 (n=27) n.s 
HLA-A*23 0.043 (n=5) 0.045 (n=24) n.s 
HLA-A*24 0.181 (n=21) 0.116 (n=61) n.s 
HLA-A*25 0.017 (n=2) 0.009 (n=5) n.s 
HLA-A*26 0.026 (n=3) 0.027 (n=14) n.s 
HLA-A*29 0.069 (n=8) 0.049 (n=26) n.s 
HLA-A*30 0.009 (n=1) 0.015(n=8) n.s 
HLA-A*31 0.017 (n=2) 0.019 (n=10) n.s 
HLA-A*32 0.026 (n=3) 0.038 (n=20) n.s 
HLA-A*33 0.060 (n=7) 0.036 (n=19) n.s 
HLA-A*66 0.009 (n=1) 0.008 (n=4) n.s 
HLA-A*68 0.035 (n=4) 0.036 (n=19) n.s 
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Table 5 Comparison of allele frequencies of HLA-A, -B  and -C between NASH patients and controls 
(Cont.). 
HLA-B 
NASH 
(n=116 alleles) 
Controls * 
(n=484 alleles) 
p value 
HLA-B*7 0.026 (n=3) 0.056 (n=27) n.s 
HLA-B*8 0.034 (n=4) 0.064 (n=31) n.s 
HLA-B*13 0.017 (n=2) 0.010 (n=5) n.s 
HLA-B*14 0.095 (n=11) 0.081 (n=39) n.s 
HLA-B*15 0.060 (n=7) 0.064 (n=29) n.s 
HLA-B*18 0.069 (n=8) 0.046 (n=22) n.s 
HLA-B*27 0.052 (n=6) 0.027 (n=13) n.s 
HLA-B*35 0.076 (n=9) 0.097 (n=47) n.s 
HLA-B*37 0.009 (n=1) 0.014 (n=7) n.s 
HLA-B*38 0.017 (n=2) 0.021 (n=10) n.s 
HLA-B*39 0.026 (n=3) 0.010 (n=5) n.s 
HLA-B*40 0.026 (n=3) 0.019 (n=9) n.s 
HLA-B*41 0.009 (n=1) 0.010 (n=5) n.s 
HLA-B*44 0.181 (n=21) 0.174 (n=83) n.s 
HLA-B*45 0.009 (n=1) 0.012 (n=6) n.s 
HLA-B*49 0.078 (n=9) 0.027 (n=13) 
0.022 (n.s 
after BC) 
HLA-B*50 0.043 (n=5) 0.048 (n=23) n.s 
HLA-B*51 0.086 (n=10) 0.106 (n=51) n.s 
HLA-B*57 0.052 (n=6) 0.029 (n=14) n.s 
HLA-B*58 0.026 (n=3) 0.012 (n=6) n.s 
HLA-C 
NASH 
(n=116 alleles) 
Controls * 
(n=414 alleles) 
p value 
HLA-C*1 0.017 (n=2) 0.012 (n=5) n.s 
HLA-C*2 0.069 (n=8) 0.065 (n=27) n.s 
HLA-C*3 0.026 (n=3) 0.056 (n=23) n.s 
HLA-C*4 0.095 (n=11) 0.176 (n=73) 
0.032 (n.s 
after BC) 
HLA-C*5 0.095 (n=11) 0.063 (n=26) n.s 
HLA-C*6 0.095 (n=11) 0.099 (n=41) n.s 
HLA-C*7 0.250 (n=29) 0.229 (n=95) n.s 
HLA-C*8 0.086 (n=10) 0.077 (n=32) n.s 
HLA-C*12 0.069 (n=8) 0.053 (n=22) n.s 
HLA-C*14 0.043 (n=5) 0.034 (n=14) n.s 
HLA-C*15 0.034 (n=4) 0.065 (n=27) n.s 
HLA-C*16 0.103 (n=12) 0.060 (n=25) n.s 
HLA-C*17 0.009 (n=1) 0.010 (n=4) n.s 
HLA-C*18 0.009 (n=1) 0 n.s 
* A previously studied population of 264 unrelated healthy subjects was used as controls. Allele frequencies 
were compared using the Fisher exact test. Bonferroni` s correction was applied (BC). 
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 The SNPs in the genes PGBD1 and ZNF193, and SNPs RS724078 and RS4713207 
were genotyped in the 59 patients and in a subgroup of controls of 56 subjects. No 
statistically significant differences were observed in the allele frequencies of these 
markers between NASH patients and controls (Table 6). 
 
Table 6 Comparison of allele frequencies of SNP markers between NASH patients and controls. 
Class2SNP  NASH Controls * 
p value 
  n=112 
RS724078 (n=118) A 0.356 (n=42) 0.384 (n=43) 
n.s 
 G 0.644 (n=76) 0.616 (n=69) 
     
RS4713207 (n=118) A 0.542 (n=64) 0.423 (n=48) 
n.s 
 G 0.466 (n=54) 0.571 (n=64) 
     
PGBD1 (n=118) A 0.644 (n=76) 0.643 (n=72) 
n.s 
 G 0.362 (n=42) 0.357 (n=40) 
     
ZNF193 (n=118) A 0.593 (n=70) 0.554 (n=62) 
n.s 
 G 0.407 (n=48) 0.446 (n=50) 
* Allele frequencies of the genetic markers were determined in the subgroup of 56 unrelated healthy 
subjects. Allele frequencies were compared using the Fisher exact test. 
 
3.2.2 HAPLOTYPE FREQUENCIES 
 Gathering all sequencing information obtained in these 8 SNP for NASH patients 
and controls, extended haplotypes were inferred using the software PHASE. In Fig.6, 
haplotypes were aligned taking in to account the HLA–A alleles and then arbitrarily 
according to the similarity of the alleles from the several genetic markers. The extended 
haplotypes that were found with frequencies above 10% were those carrying the HLA-
A*2, HLA-A*24 and HLA-A*1. Although there are some conserved regions in those 
haplotypes, they are extremely diverse as illustrated in Figure 6 by use of different colors. 
Interestingly, the extended haplotypes carrying HLA-A*29 and HLA-A*33 showed a high 
conservation. 50% (4/8) of HLA-A29 and 57% (4/7) of HLA-A33 haplotype carry the same 
alleles in all 8 markers tested (Fig. 6 and Table 7). 
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Figure 6 Extended haplotypes using 8 genetic markers of the MHC region, in NASH patients 
grouped according HLA-A types. Color boxes represent conserved haplotypes areas. 
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3.3 ANALYSES OF THE IMPACT OF GENETIC MARKERS OF THE MHC REGION IN RELATION TO 
SEVERITY OF DISEASE  
 
 For these analyses allele frequencies of each genetic marker were determined in 
relation to severity of NASH. Severity of disease was evaluated in liver biopsies scored for 
levels of steatosis, inflammation, fibrosis and siderosis. In order to have sufficient number 
of patients for statistical analyses, patients were grouped in two classes: 1 and >1 for 
steatosis and inflammation and 0 and ≥1 for fibrosis and siderosis. For steatosis, 
inflammation and siderosis, no statistically significant effect was found for any of the 
genetic markers tested (Fisher exact test, p>0.05). When fibrosis was analyzed, a high 
frequency of the HLA-A*33 was found in patients with fibrosis ≥1 (6/46=0.130) in contrast 
with patients without fibrosis (1/66=0.015, p=0.018, Fisher exact test). A low frequency of 
HLA-A*29 was found in patients with fibrosis ≥1 (1/46=0.022) in contrast with patients 
without fibrosis (7/66=0.106), although this result does not reach statistical significance 
(p=0.137). 
 
3.4 ANALYSES OF CD8+T CELLS NUMBERS IN RELATION TO SEVERITY OF DISEASE 
 
 The numbers of CD8+T lymphocytes were analyzed in relation to severity of NASH 
using the same grouping criteria of biopsy parameters in two classes as above. 
 A statistically significant association was found between CD8+T cell numbers and 
fibrosis. Patients without fibrosis showed average CD8+T cell numbers higher (0.49±0.17 
x106/ml) than patients with fibrosis ≥1 (0.37±0.16x106/ml, p=0.044 Student-T test) (Fig.7). 
A negative association was also found between CD8+T cell numbers and inflammation 
(0.46±0.17 for inflammation=1 and 0.29±0.15 x106/ml for inflammation >1, p=0.045, 
Student T-test) (Fig.8). 
 No statistically significant associations were found for total lymphocytes and CD4+ 
T cells counts and any of the liver histological parameters analyzed. 
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Figure 7 Distribution of CD8+ T cell numbers according to fibrosis score (p=0,044). 
 
Figure 8 Distribution of CD8+T cell numbers according to inflammation score (p=0,045). 
 
3.5 IMPACT OF EXTENDED HAPLOTYPE AND CD8+ T CELLS NUMBERS IN HEPATIC FIBROSIS IN 
NASH PATIENTS  
 
 According to previously published results in HH subjects [7], genetic markers of 
the MHC Class I region were shown to be predictors of CD8+T cell numbers. In the context 
of C282Y mutation, the inheritance of two haplotypes carrying the HLA-A*01, -A*02 or -
A*03 were associated with a low CD8+T cell profile in opposite to haplotypes carrying all 
Fibrosis =0 Fibrosis ≥1 
  
  
Inflammation =1 Inflammation ≥1 
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other HLA-A alleles. Results in NASH patients showed an impact of certain HLA-A types on 
fibrosis and negative associations of CD8+ T cells with fibrosis and inflammation. In face of 
the results previously described in HH patients and the results described in the present 
study, we went further to test the hypothesis if in this disease the impact of HLA-A region 
on severity of NASH is mediated by CD8+T cell numbers. For this, we analyzed extended 
haplotypes carrying HLA-A*33 and HLA-A*29 (the most conserved haplotypes among this 
group of NASH patients) in relation to CD8+T cell numbers and degree of fibrosis (Table 
7). Indeed, in the subgroup of patients carrying the allele HLA-A*33, where all patients 
had fibrosis except one, the average of CD8+T cell number was low (0.31±0.19 x106/ml). 
In contrast, the subgroup of patients carrying the HLA-A*29, where there is only one 
patient with fibrosis, had high average of CD8+T cell numbers (0.51±0.16 x106/ml). 
 
Table 7 Genetic characterization of NASH patients carrying HLA-A*29 and HLA*A33 haplotype 
with correspondent CD8+T cell counts and Fibrosis score of liver biopsy. 
* n.a: not available 
 
ID Gender 
Age Fibrose CD8 Haplotype 1 Haplotype 2 
(years) Score (x106 ml) HLA-B HLA-C HLA-A RS078 RS207 PGBD ZNF193 HFE HLA-B HLA-C HLA-A RS078 RS207 PGBD ZNF193 HFE 
#1166 M 47 0 n.a 44 16 29 G A G G H63D 44 16 29 G A G G H63D 
#1849 F 33 0 0.57 44 16 29 G A G G H63D 49 7 26 G G A A wt 
#993 F 68 0 0.66 44 16 29 G A G G H63D 18 7 24 G G A A wt 
#1291 F 34 0 n.a 44 16 29 G G G G H63D 27 2 24 G G A A wt 
#1611 M 45 0 0.62 44 16 29 G A G G wt 49 7 68 G A G G wt 
#930 F 31 1 0.27 14 8 29 G G G G H63D 58 7 26 A G A A wt 
#1416 M 26 0 0.41 35 4 29 A A A A wt 15 2 24 G G A A wt 
#1036 M 66 2 0.07 14 8 33 G G G G wt 49 7 3 A G G G H63D 
#827 F 33 1 0.31 14 8 33 G G G G wt 35 4 2 A G A A wt 
#986 M 39 1 0.51 14 8 33 G G G G wt 15 7 66 G A A A wt 
#997 M 36 1 0.35 14 8 33 G G G G wt 8 7 1 A A A A H63D 
#685 M 62 1 0.33 14 6 33 G G G G H63D 13 6 1 G A A A H63D 
#1216 M 43 0 0.43 14 8 33 G G G G C282Y 14 8 3 A G A A wt 
#1345 F 45 2 0.70 14 8 33 G G A A wt 51 2 3 A A A A H63D 
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4-DISCUSSION 
 
 Low numbers of CD8+T cells have been described for a long time in HH and have 
been associated with the severity of disease in terms of iron stores, HH related clinical 
symptoms and progression of liver pathology [27]. In addition, genes localized at the MHC 
Class I region were shown to be involved in the regulation of CD8+T cell numbers and 
therefore associated with the severity of disease. In the present work, we studied the 
involvement of the same modifiers of the severity of HH (CD8+T cells and genetic markers 
of MHC Class I region) in the phenotypic expression of NASH in 59 patients. 
From general characterization of subjects, the results showed that in this group of 
NASH patients, serum AST and ALT are increased. Moreover, we also found positive 
associations of the degree of inflammation and fibrosis with ALT levels. These results are 
expected since these enzymes are markers of liver injury. In fact it is known that long-
term observation of these enzymes may provide an index of individuals at risk of 
developing metabolic syndrome and diabetes [28]. Siderosis was found to be associated 
with serum ferritin, showing that the levels of ferritin are indicating liver iron stores. 
 
The involvement of MHC Class I genetic markers in NASH is different from HH 
NASH patients were genotyped for 8 markers of the MHC class I region, including 
HLA-A, -B and-C, HFE mutations (C282Y and H63D) and four SNPs in between (Fig. 5). In 
general, no differences were found in the frequencies of those markers between NASH 
patients and controls. Allele frequencies of HFE mutations (C282Y and H63D) were not 
statistically significant different between patients and controls, although we found a 
slightly increase of the H63D (0.024 versus 0.191). The frequencies of these mutations 
have been previously reported and some authors found increased frequencies mainly of 
the H63D [20, 29-31]. Nevertheless, this was not confirmed by other studies [32-34]. This 
may be due to selection criteria of patients in those studies or to geographical population 
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genetic differences. No significant differences were found between NASH patients and 
controls for the frequencies of the HLA-A, -B and –C. Although statistical results were 
found for HLA-B*49 and –C*04 these differences do not have statistical power 
considering that we made multiple comparisons. 
Extended haplotypes showed a high diversity of the genetic markers studied when 
they are analyzed according to the HLA-A alleles (Fig. 6). The most conserved extended 
haplotypes are the ones carrying the A*29 and A*33 where they have the same alleles in 
the 8 markers in 50% of the A*29 haplotypes and in 57% of the A*33 haplotypes. These 
findings are considerable different from genetics of the same region in HH where 
haplotypes carring the C282Y mutation are extremely conserved as shown before [7]. 
 
CD8+T lymphocytes are related with liver severity in NASH 
In NASH patients, CD8+T cell numbers were found associated with severity of this 
disease in terms of degree of fibrosis. Patients with low CD8+T cell numbers had high 
degree of fibrosis in contrast with patients with high CD8+T cells that had less fibrosis. 
This result does not seem to be due to the liver iron content as previously described in HH 
[12, 13], because siderosis or HIC did not correlate with CD8+T cells. There are two 
possible explanations for these results. One is related with the iron accumulation in the 
liver that is not as severe as in HH that may prevent the observation of the referred 
correlation. The other is related with the presence of inflammation in NASH, where 
CD8+T cell numbers are inversely associated with liver inflammation. This is clearly in 
contrast with what is described in HH [14]. These results suggest distinct pathogeneses in 
these two diseases. 
 
Is there any combined effect of MHC Class I genes and CD8+T cells in liver severity in 
NASH? 
 Interestingly, we found an association of the two most conserved haplotypes 
(A*33 and A*29) with fibrosis and CD8+T cell numbers. While patients carrying HLA-A*33 
 MHC-Class I markers in non-alcoholic steatohepatitis  
 
28 
haplotype had more fibrosis and less CD8+ T cells, patients carrying HLA-A*29 haplotype 
had less fibrosis and high CD8+T cells. It is possible that in this region there is one or more 
genes correlated with CD8+T cells and with fibrosis. In this case “protective” gene/s 
would be transmitted in the haplotype carrying HLA-A*29 (associated with high CD8+T 
cells and low fibrosis) and “susceptibility” gene/s would be transmitted in the haplotype 
carrying the HLA-A*33 (associated with low CD8+T cells and high fibrosis). These results 
may be observed only in the context of these two haplotypes because there is a great 
conservation of the analyzed region that could allow the transmission of long blocks 
carrying the same genes through generations. It should be noticed however, that the 
variability of CD8+T cell is high in each subgroup and the number of patients with those 
HLA-A alleles is small probably due to their normal low frequencies (less than 5%) (Table 
5). 
 Considering genes located at the MHC region, near the HLA-B gene there is the 
TNF(α) that is recognized as an important intervenient in the activation of the stellate 
cells which drives fibrosis [35]. Other genes in the region are transcription factors with 
unknown functions that could directly or indirectly regulate expression of distant genes. 
Therefore we should not exclude an important role of other non-MHC Class I 
linked cytokines. It has been described that toll-like receptor (TLR)-9 and MCP-1 cytokine 
are expressed by activated stellate cells and are responsible for lymphocyte T cells 
placement in injury tissues [24, 36]. Stellate cells are antigen-presenting cells and can 
regulate, through chemokines, the infiltration of inflammatory cells. Another toll-like 
receptor, TLR-4, produced by Kupffer and stellate cells, is also able to interact with 
endotoxins, resulting in the release of pro-inflammatory mediators that can induce 
hepatic injury and fibrosis [22, 36]. Moreover a polymorphism in TRL-4 gene has been 
reported to contribute to fibrosis progression in HCV infection [28]. 
 It is evident that the mechanism of fibrogenesis is complex and any step towards 
its clarification is of great clinical relevance. 
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5-CONCLUSION 
 
 Motivated by the known importance of the MHC region in liver pathology, as 
demonstrated by the well studied model of HH, this study aimed to search its 
contribution in NASH metabolic syndrome. In a group of 59 NASH patients with available 
biopsy evaluation, we found an association between the criteria of fibrosis and CD8+ T 
cell numbers, being these variables inversely associated. The inflammatory condition is 
the main physiological difference between NASH and HH pathology. In NASH, peripheral 
low numbers of CD8+ T cells reflect tissue liver inflammation, while in HH low CD8+ T cells 
reflect a genetic predisposition. Furthermore, the MHC region in this NASH population is 
highly variable. Despite that, two conserved haplotypes carrying HLA*A33 and A*29 
appeared and were related to a fibrosis predisposition state. This genetic region is very 
complex and contains many genes, some being transcription factors that could regulate 
the expression of distant genes. With the present study we gained in terms of increasing 
our knowledge in NASH pathology and the role of CD8+T cell lymphocytes in the 
fibrogenic process. The results presented here, however, were obtained with the 
peripheral blood cells, it would be important in future to confirm the role of CD8+T cells 
in liver tissue. 
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